| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 13,013.0 | 11,369.0 |
| Profit before tax | 1,231.0 | 2,180.0 |
| Net income | 920.0 | 1,644.0 |
| EPS (diluted, $ a share) | $0.53 | $0.94 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -44.0% |
|---|---|
| Revenue, year on year | +14.5% |
| Operating margin | 10.4% |
10-Q filed with the SEC, NYSE: ABT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Abbott Laboratories: key numbers
- Share price
- $107.45Close, Nov 16
- Market cap
- $186B
- Shares outstanding
- 1.73BLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Abbott Laboratories
All →Abbott Laboratories Executive Compensation
Abbott Laboratories extended the term of its Change in Control Agreements for its named executive officers through December 31, 2028. The agreement for Chairman and CEO Robert B. Ford was not extended and is set to expire on December 31, 2026.
- Term
- through Dec 2028
Abbott Laboratories EVP Mary K. Moreland Sells $406K of Stock
Mary K. Moreland, EVP, sold 3,500 shares of Abbott Laboratories at $116.00 a share, worth $406K in total on Nov 5, 2026. Shares held after the trade: 100,791 (-3.4%).
- Value
- $406K
- Shares
- 3,500
- Price
- $116.00
- Role
- EVP
- Holding change
- -3.4%
- Trade date
- Nov 5, 2026
Abbott Laboratories Divestiture
Abbott Laboratories announced its intention to separate its global Nutrition business into an independent, publicly traded company via a tax-free distribution to shareholders. The new entity will be a global leader in healthy nutrition with approximately $8.5 billion in annual sales and a portfolio including brands like Similac, Ensure, and PediaSure. The separation is expected to be completed by the end of 2027.
“As we continue to shape Abbott for the future, this separation will benefit both companies, setting each one up for maximum success in its respective market. Our Nutrition business has a unique opportunity to capitalize on the growing demand for healthy nutrition, and it will be better positioned as an independent company to more effectively direct its strategic resources across its priorities.”
Robert B. Ford, chairman and chief executive officer, Abbott
Abbott Laboratories Financial Results
Abbott Laboratories reported third-quarter 2026 sales of $13.01 billion, a 14.5% increase on a reported basis, driven by strong performance in its Diagnostics and Medical Devices segments. The company tightened its full-year 2026 adjusted diluted EPS guidance to a range of $5.50 to $5.55 and highlighted several new product approvals, including the Libre Duo biowearable sensor.
- Term
- Q3 2026
“Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio. With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead.”
Robert B. Ford, chairman and chief executive officer, Abbott